
Revolution Medicines, Inc. – NASDAQ:RVMD
Revolution Medicines stock price today
Revolution Medicines stock price monthly change
Revolution Medicines stock price quarterly change
Revolution Medicines stock price yearly change
Revolution Medicines key metrics
Market Cap | 7.91B |
Enterprise value | 1.58B |
P/E | -6.85 |
EV/Sales | 44.83 |
EV/EBITDA | -6.54 |
Price/Sales | 47.58 |
Price/Book | 2.45 |
PEG ratio | 0.34 |
EPS | -3.75 |
Revenue | N/A |
EBITDA | -550.02M |
Income | -484.27M |
Revenue Q/Q | -100% |
Revenue Y/Y | -86.88% |
Profit margin | -702.95% |
Oper. margin | -730.01% |
Gross margin | 0% |
EBIT margin | -730.01% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRevolution Medicines stock price history
Revolution Medicines stock forecast
Revolution Medicines financial statements
$63.86
Potential upside: 74.75%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 3.82M | -98.29M | -2570.55% |
---|---|---|---|
Sep 2023 | 0 | -108.43M | |
Dec 2023 | 742K | -161.53M | -21770.49% |
Mar 2024 | 0 | -116.00M |
Jun 2023 | 1073709000 | 142.87M | 13.31% |
---|---|---|---|
Sep 2023 | 984232000 | 146.77M | 14.91% |
Dec 2023 | 2088591000 | 262.39M | 12.56% |
Mar 2024 | 1908362000 | 182.89M | 9.58% |
Jun 2023 | -67.12M | -43.54M | 64.63M |
---|---|---|---|
Sep 2023 | -100.49M | 77.35M | 1.01M |
Dec 2023 | -120.56M | -380.40M | 839.35M |
Mar 2024 | -160.56M | -247.96M | 810K |
Revolution Medicines alternative data
Aug 2023 | 259 |
---|---|
Sep 2023 | 292 |
Oct 2023 | 292 |
Nov 2023 | 292 |
Dec 2023 | 338 |
Jan 2024 | 338 |
Feb 2024 | 338 |
Mar 2024 | 378 |
Apr 2024 | 378 |
May 2024 | 378 |
Jun 2024 | 411 |
Jul 2024 | 411 |
Revolution Medicines other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 18167 |
Mar 2024 | 0 | 38509 |
Apr 2024 | 0 | 19655 |
May 2024 | 0 | 11500 |
Jun 2024 | 0 | 55120 |
Jul 2024 | 0 | 56221 |
Aug 2024 | 0 | 26667 |
Sep 2024 | 0 | 41076 |
Oct 2024 | 0 | 132866 |
Nov 2024 | 0 | 95220 |
Dec 2024 | 1304347 | 24940 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | GOLDSMITH MARK A director, officer.. | Common Stock | 30,846 | $0.49 | $15,115 | ||
Option | GOLDSMITH MARK A director, officer.. | Stock Option (Right to Buy) | 30,846 | $0.49 | $15,115 | ||
Sale | KELSEY STEPHEN MICHAEL officer: See Remarks | Common Stock | 4,663 | $45.4 | $211,719 | ||
Sale | HORN MARGARET A officer: Chief Op.. | Common Stock | 4,329 | $45.4 | $196,554 | ||
Sale | GOLDSMITH MARK A director, officer.. | Common Stock | 11,714 | $45.4 | $531,862 | ||
Sale | CISLINI JEFF officer: General Counsel | Common Stock | 1,599 | $45.4 | $72,601 | ||
Sale | ANDERS JACK officer: Chief Financial Officer | Common Stock | 2,635 | $45.4 | $119,640 | ||
Purchase | SCHROEDER THILO director | Common Stock | 543,478 | $46 | $24,999,988 | ||
Purchase | SCHROEDER THILO director | Common Stock | 760,869 | $46 | $34,999,974 | ||
Sale | CISLINI JEFF officer: General Counsel | Common Stock | 2,554 | $55.13 | $140,812 |
Patent |
---|
Application Filling date: 11 Jun 2021 Issue date: 12 May 2022 |
Application Filling date: 10 Jun 2021 Issue date: 12 May 2022 |
Application Filling date: 2 Mar 2020 Issue date: 5 May 2022 |
Application Filling date: 15 Sep 2021 Issue date: 7 Apr 2022 |
Application Filling date: 21 Dec 2020 Issue date: 17 Mar 2022 |
Application Filling date: 6 Apr 2021 Issue date: 3 Feb 2022 |
Grant Utility: Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2- -oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor Filling date: 26 Feb 2021 Issue date: 11 Jan 2022 |
Application Filling date: 28 Jan 2021 Issue date: 30 Dec 2021 |
Grant Filling date: 23 Dec 2020 Issue date: 9 Nov 2021 |
Application Filling date: 28 Oct 2020 Issue date: 4 Nov 2021 |
Quarter | Transcript |
---|---|
Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 26 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Mark A. Goldsmith Ph.D. (1962) Chief Executive Officer, Pres & Chairman | $962,010 |
Dr. Stephen M. Kelsey M.D., FRCP, FRC Path. (1961) Pres of R&D | $739,910 |
Ms. Margaret A. Horn (1963) Chief Operating Officer, Gen. Counsel & Sec. | $735,390 |
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Revolution Medicines: A Big Pipeline In Need Of Big Data
Revolution Medicines' Strategic Edge In RAS-Driven Oncology
Revolution Medicines: Early-Stage Firm Whose High Valuation I Cannot Explain
Revolution Medicines: Highly Differentiated Offering Gaining Traction
-
What's the price of Revolution Medicines stock today?
One share of Revolution Medicines stock can currently be purchased for approximately $36.54.
-
When is Revolution Medicines's next earnings date?
Unfortunately, Revolution Medicines's (RVMD) next earnings date is currently unknown.
-
Does Revolution Medicines pay dividends?
No, Revolution Medicines does not pay dividends.
-
How much money does Revolution Medicines make?
Revolution Medicines has a market capitalization of 7.91B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 67.27% to 11.58M US dollars.
-
What is Revolution Medicines's stock symbol?
Revolution Medicines, Inc. is traded on the NASDAQ under the ticker symbol "RVMD".
-
What is Revolution Medicines's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Revolution Medicines?
Shares of Revolution Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Revolution Medicines's key executives?
Revolution Medicines's management team includes the following people:
- Dr. Mark A. Goldsmith Ph.D. Chief Executive Officer, Pres & Chairman(age: 63, pay: $962,010)
- Dr. Stephen M. Kelsey M.D., FRCP, FRC Path. Pres of R&D(age: 64, pay: $739,910)
- Ms. Margaret A. Horn Chief Operating Officer, Gen. Counsel & Sec.(age: 62, pay: $735,390)
-
How many employees does Revolution Medicines have?
As Jul 2024, Revolution Medicines employs 411 workers, which is 9% more then previous quarter.
-
When Revolution Medicines went public?
Revolution Medicines, Inc. is publicly traded company for more then 5 years since IPO on 13 Feb 2020.
-
What is Revolution Medicines's official website?
The official website for Revolution Medicines is revmed.com.
-
Where are Revolution Medicines's headquarters?
Revolution Medicines is headquartered at 700 Saginaw Drive, Redwood City, CA.
-
How can i contact Revolution Medicines?
Revolution Medicines's mailing address is 700 Saginaw Drive, Redwood City, CA and company can be reached via phone at +65 04816801.
-
What is Revolution Medicines stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Revolution Medicines in the last 12 months, the avarage price target is $63.86. The average price target represents a 74.75% change from the last price of $36.54.
Revolution Medicines company profile:

Revolution Medicines, Inc.
revmed.comNASDAQ
490
Biotechnology
Healthcare
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Redwood City, CA 94063
CIK: 0001628171
ISIN: US76155X1000
CUSIP: 76155X100